New drug combo shows promise for Tough-to-Treat stomach cancers
NCT ID NCT07546812
First seen Apr 25, 2026 · Last updated Jun 20, 2026 · Updated 6 times
Summary
This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how long participants live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Denikitug (also called GS-1811), given alone or with nivolumab, ramucirumab, or paclitaxel
What this could lead to
If successful, this could provide a new treatment option for people with advanced stomach or esophageal cancer that has stopped responding to initial therapy.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.